Toripalimab Combined with Bevacizumab Plus Chemotherapy as First-Line Treatment for Refractory Recurrent or Metastatic Cervical Cancer: A Single-Arm, Open-Label, Phase II Study (JS001-ISS-CO214)

crossref(2024)

引用 0|浏览4
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要